Jingping Li
Hebei Provincial Key Laboratory Of Tumor Microenvironment And Drug Resistance
Shijiazhuang, 050000, China
Shijiazhuang, 050000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer.
Journal: Oncology research
Published: November 29, 2024
IFIH1 promotes apoptosis through the TBK1/IRF3 pathway in triple-negative breast cancer.
Journal: Neoplasma
Published: June 14, 2024
Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment.
Journal: Medicine
Published: September 29, 2023
The expression landscape of FOXP3 and its prognostic value in breast cancer.
Journal: Annals of translational medicine
Published: May 30, 2022
Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
Journal: Medicine
Published: July 27, 2021
Circ_0,007,331 Promotes the PTX Resistance and Progression of Breast Cancer via miR-200b-3p/ANLN.
Journal: The Journal of surgical research
Published: July 18, 2021
Exosome miR-134-5p restrains breast cancer progression via regulating PI3K/AKT pathway by targeting ARHGAP1.
Journal: The journal of obstetrics and gynaecology research
Published: January 18, 2021
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.
Journal: Annals of translational medicine
Published: November 04, 2020
Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: October 22, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026